Intravenous Immune Globulin Therapy in Dermatomyositis
- 6 October 2022
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (14) , 1320-1321
Abstract
Dermatomyositis is a heterogeneous syndrome with several associated antibodies, such as those against transcription intermediary factor 1-γ (anti–TIF-1γ), melanoma differentiation-associated gene 5 (anti–MDA-5), nuclear matrix protein 2 (anti–NXP-2), and small ubiquitin-like modifier–activating enzyme (anti-SAE). Each of these antibodies is referred to by neurologists and rheumatologists by its acronym for convenience,1 and each is associated with distinct clinical and histopathological features.2 More than 30 years ago, dermatomyositis was thought to be caused by complement-mediated microangiopathy, but there is evidence that the microvasculopathy and skin and muscle damage associated with dermatomyositis are due primarily to toxicity from pathways mediated by type I . . .Keywords
This publication has 9 references indexed in Scilit:
- Trial of Intravenous Immune Globulin in DermatomyositisNew England Journal of Medicine, 2022
- Type I Interferons in Dermatomyositis MyoblastsNeurology, 2022
- DermatomyositisNeurology, 2022
- Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With Myositis‐Specific AutoantibodiesArthritis & Rheumatology, 2022
- Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific AutoantibodiesJAMA Neurology, 2018
- Classification and management of adult inflammatory myopathiesThe Lancet Neurology, 2018
- 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative InitiativeArthritis & Rheumatology, 2017
- Interferon‐α/β–mediated innate immune mechanisms in dermatomyositisAnnals of Neurology, 2005
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975